<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24388" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Loading Dose</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Miniaci</surname>
            <given-names>Anthony</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anthony Miniaci declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24388.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">Loading doses are a&#x000a0;means to&#x000a0;quicks achieve therapeutic drug concentrations or&#x000a0;prompt an immediate clinical response. Loading doses are larger than maintenance doses and are usually administered as a single bolus, although some drugs (eg, amiodarone or digoxin) may require multiple loading doses administered over several hours to days.<xref ref-type="bibr" rid="article-24388.r1">[1]</xref>&#x000a0;An&#x000a0;intravenous loading dose of phenytoin, on the other hand, should be&#x000a0;administered as a single dose. Medications with shorter half-lives (eg, heparin for treating pulmonary embolism) may also&#x000a0;require a loading dose to&#x000a0;achieve their therapeutic effect immediately.</p>
        <p>In medicine, the treatment for most conditions uses various pharmacological medications. For each of these individual medications, the route of administration, appropriate dosage, and frequency of use are determined by the medication&#x02019;s pharmacokinetics (PK). Pharmacokinetics is the relationship between an administered dose of a drug and its measured concentration within the body. An individual medication&#x02019;s PK is governed by how it moves within the body through absorption, bioavailability, distribution, metabolism, and excretion.</p>
        <p>The characteristics that define an individual medication&#x02019;s PK can help determine the&#x000a0;<italic toggle="yes">loading dose.</italic>&#x000a0;While a patient takes a specific drug to achieve the therapeutic benefit, the drug must reach a certain steady-state concentration.<xref ref-type="bibr" rid="article-24388.r2">[2]</xref>&#x000a0;Typically, for any medication, five to seven half-lives are required for this to be achieved.</p>
        <table-wrap id="article-24388.table0" position="float" orientation="portrait">
          <table style="width: 322px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 130.359px;" rowspan="1" colspan="1">
<bold># of Half Lives</bold>
</td>
                <td style="width: 121.641px;" rowspan="1" colspan="1">
<bold>% of Steady State</bold>
</td>
              </tr>
              <tr>
                <td style="width: 130.359px;" rowspan="1" colspan="1">1</td>
                <td style="width: 121.641px;" rowspan="1" colspan="1">50%</td>
              </tr>
              <tr>
                <td style="width: 130.359px;" rowspan="1" colspan="1">2</td>
                <td style="width: 121.641px;" rowspan="1" colspan="1">75%</td>
              </tr>
              <tr>
                <td style="width: 130.359px;" rowspan="1" colspan="1">3</td>
                <td style="width: 121.641px;" rowspan="1" colspan="1">87.5%</td>
              </tr>
              <tr>
                <td style="width: 130.359px;" rowspan="1" colspan="1">4</td>
                <td style="width: 121.641px;" rowspan="1" colspan="1">93.8%</td>
              </tr>
              <tr>
                <td style="width: 130.359px;" rowspan="1" colspan="1">5</td>
                <td style="width: 121.641px;" rowspan="1" colspan="1">96.9%</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Reaching this concentration is typically not an issue for drugs with short half-lives; however, other medications or conditions may require a more rapid therapeutic onset. For instances where a therapeutic steady-state concentration is needed immediately, loading doses can be utilized to achieve this therapeutic concentration more rapidly.<xref ref-type="bibr" rid="article-24388.r2">[2]</xref></p>
        <p>A loading dose is typically calculated through the following formula:</p>
        <p>
<bold>L<sub>D</sub>=(Volume of Distribution X Steady State Concentration)/(Bioavailability X Drug Fraction of Salt Form that is Active Drug)</bold>
</p>
        <p>For this formula, concentration steady-state is defined as the therapeutic concentration of medication in the body, while bioavailability is the fraction of an administered dose that reaches systemic circulation. For intravenous drugs, the bioavailability = 1 because the drug is injected directly into the bloodstream. For orally administered drugs, the bioavailability will be affected by several factors, including first-pass metabolism, absorption, etc). The volume of distribution is typically calculated as follows:</p>
        <p>
<bold>V<sub>d</sub>=Dose of Medication Given/Concentration in the Plasma</bold>
</p>
        <p>The calculation of the loading dose should not be confused with the maintenance dose, which is the dose required to maintain steady-state concentration. This calculation is:&#x000a0;</p>
        <p>
<bold>M<sub>D</sub>=(Concentration Steady State X Clearance X Dosing Interval)/Bioavailability</bold>
</p>
        <p>Clearance can be determined using the known half-life of a medication, which is the time required for a dose to reach 50% of its initial plasma concentration. Clearance can ultimately be determined through the following:&#x000a0;</p>
        <p>
<bold>CL=(0.693 X V<sub>d</sub>)/ Half-life</bold>
</p>
      </sec>
      <sec id="article-24388.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>When prescribing a loading dose of a new medication, there are many factors that a clinician&#x000a0;must consider. Through the formulas above, the loading dose of any drug is influenced by many of the&#x000a0;pharmacokinetic variables.&#x000a0;Loading doses are challenging to calculate, as they&#x000a0;necessitate multistep calculations&#x000a0;utilizing&#x000a0;patient data (such as weight) and the&#x000a0;specific drug (eg, the estimated volume of distribution or drug half-life). Staff may mistakenly continue loading doses instead of lowering to maintenance doses, particularly when patients&#x000a0;transfer between care settings (such&#x000a0;as from the&#x000a0;emergency department to&#x000a0;being admitted to the floor&#x000a0;or at discharge from the hospital back to outpatient status).</p>
        <p>Bioavailability is typically affected by the route of administration of the medication. Each medication typically has a route of administration that provides the best bioavailability. For example, in one study, researchers found that sublingual administration of misoprostol had significantly higher bioavailability than&#x000a0;oral administration.<xref ref-type="bibr" rid="article-24388.r3">[3]</xref>&#x000a0;</p>
        <p>Higher bioavailability allows for the utilization of a lower loading dose to reach the same steady-state concentration, leading to better medication safety and efficacy. Patient comorbidities can also affect medication bioavailability. For example, celiac disease causes atrophy of the duodenal villi, which can hinder the absorption and bioavailability of medications given orally. As a result, other drugs have been developed to allow proper treatment for these patients, such as a medication to increase iron absorption in patients with celiac disease and iron deficiency anemia.<xref ref-type="bibr" rid="article-24388.r4">[4]</xref></p>
        <p>Further, various physiological factors can affect the concentration and pharmacokinetics of medication. One study found that the clearance of ciprofloxacin significantly decreases with age and worsening kidney function.<xref ref-type="bibr" rid="article-24388.r5">[5]</xref>&#x000a0;Failure to adjust for these factors could lead to toxicity or other related side effects. Ultimately, it is essential to consider all factors while dosing medications, as any change in these variables, will inevitably affect the loading dose and, consequently, steady-state concentration.</p>
      </sec>
      <sec id="article-24388.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>A medication&#x02019;s loading dose has many vital clinical applications. In emergencies, drugs must reach therapeutic concentration rapidly, often requiring a loading dose. For example, studies have found that a loading dose of levetiracetam is essential for adequate treatment of status epilepticus.<xref ref-type="bibr" rid="article-24388.r6">[6]</xref>&#x000a0;Loading doses require&#x000a0;</p>
        <p>Also, knowing factors that may affect a medication&#x02019;s loading dose is imperative to pharmacological treatments for chronic conditions. For example, initiation of dofetilide for treating atrial fibrillation requires an initial loading dose before reaching therapeutic concentrations. As a clinician administers this medication, they must monitor creatinine clearance and QTc interval length and adjust the dosage accordingly to avoid potentially deadly side effects such as ventricular tachycardia.<xref ref-type="bibr" rid="article-24388.r7">[7]</xref></p>
      </sec>
      <sec id="article-24388.s4" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>Using pharmacological therapy to treat a patient's underlying condition is common in today's medical field. Although these therapies can be beneficial, they can also cause significant harm to the patient. One study found that almost 11% of prescriptions have errors, and 16% of these errors result in harm to the patient.<xref ref-type="bibr" rid="article-24388.r8">[8]</xref>&#x000a0;This situation makes it essential that dosing medications are done with an interprofessional team to ensure efficacy and safety. Ways to help facilitate this would be by:</p>
        <list list-type="bullet">
          <list-item>
            <p>Having an open line of communication between all clinicians and specialties&#x000a0;&#x02013; this is especially true in instances of transition of care</p>
          </list-item>
          <list-item>
            <p>Ensure clinicians and pharmacists work together to ensure proper dosing and medication choice</p>
          </list-item>
          <list-item>
            <p>Order drug blood concentrations when clinically appropriate</p>
          </list-item>
          <list-item>
            <p>Educate family and patient about potential adverse drug reactions</p>
          </list-item>
          <list-item>
            <p>Ensure appropriate specialties are involved with the care of a patient when deemed appropriate</p>
          </list-item>
          <list-item>
            <p>Computerized prescribing and order entry systems should have dosing checks to flag&#x000a0;potential dosing errors&#x000a0;and offer recommendations for correct dosing.</p>
          </list-item>
        </list>
        <p>Interprofessional efforts become even more essential when a situation with a patient becomes more critically ill, requiring higher levels of care. By working in an interprofessional team, patient outcomes can improve, and medication errors can be avoided.<xref ref-type="bibr" rid="article-24388.r9">[9]</xref>&#x000a0;[Level 4]</p>
      </sec>
      <sec id="article-24388.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24388&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24388">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24388/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24388">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24388.s6">
        <title>References</title>
        <ref id="article-24388.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haffajee</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Love</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Canada</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Lesko</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Asdourian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias.</article-title>
            <source>Circulation</source>
            <year>1983</year>
            <month>Jun</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>1347</fpage>
            <page-range>1347-55</page-range>
            <pub-id pub-id-type="pmid">6851030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24388.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Lannoy</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2014</year>
            <month>Jan</month>
            <day>01</day>
            <volume>87</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-120</page-range>
            <pub-id pub-id-type="pmid">24055064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24388.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wide-Swensson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A Relative Bioavailability Study of Two Misoprostol Formulations Following a Single Oral or Sublingual Administration.</article-title>
            <source>Front Pharmacol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>50</fpage>
            <pub-id pub-id-type="pmid">32116725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24388.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giancotti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Talarico</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Marrazzo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gangemi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Miniero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bertini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Feralgine&#x02122; a New Approach for Iron Deficiency Anemia in Celiac Patients.</article-title>
            <source>Nutrients</source>
            <year>2019</year>
            <month>Apr</month>
            <day>20</day>
            <volume>11</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">31009990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24388.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gai</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Bo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>[Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection].</article-title>
            <source>Zhonghua Yi Xue Za Zhi</source>
            <year>2015</year>
            <month>May</month>
            <day>26</day>
            <volume>95</volume>
            <issue>20</issue>
            <fpage>1581</fpage>
            <page-range>1581-5</page-range>
            <pub-id pub-id-type="pmid">26463606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24388.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>R&#x000f6;sche</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dudek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Teleki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Godau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>B&#x000f6;sel</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Levetiracetam for treatment of status epilepticus - an update].</article-title>
            <source>Fortschr Neurol Psychiatr</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>87</volume>
            <issue>6</issue>
            <fpage>357</fpage>
            <page-range>357-363</page-range>
            <pub-id pub-id-type="pmid">31261415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24388.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torp-Pedersen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brendorp</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>K&#x000f8;ber</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>2695</fpage>
            <page-range>2695-704</page-range>
            <pub-id pub-id-type="pmid">11060831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24388.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Medication errors: the importance of an accurate drug history.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>671</fpage>
            <page-range>671-5</page-range>
            <pub-id pub-id-type="pmid">19594536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24388.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakker</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Klopotowska</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>de Keizer</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>van Marum</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van der Sijs</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>de Lange</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>de Jonge</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abu-Hanna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dongelmans</surname>
                <given-names>DA</given-names>
              </name>
              <collab>SIMPLIFY Study Group</collab>
            </person-group>
            <article-title>Improving medication safety in the Intensive Care by identifying relevant drug-drug interactions - Results of a multicenter Delphi study.</article-title>
            <source>J Crit Care</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>57</volume>
            <fpage>134</fpage>
            <page-range>134-140</page-range>
            <pub-id pub-id-type="pmid">32145656</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
